Kim JK - Search Results

1

In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.

Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S. Shin SS, et al. Among authors: kim jy, kim jk. J Med Chem. 2004 Feb 12;47(4):792-804. doi: 10.1021/jm020545z. J Med Chem. 2004. PMID: 14761182

2

A facile one-pot synthesis of 4,5-diaryl-2,2-dimethyl-3(2H)-furanones.

Lee KW, Choi YH, Joo YH, Kim JK, Shin SS, Byun YJ, Kim Y, Chung S. Lee KW, et al. Among authors: kim jk, kim y. Bioorg Med Chem. 2002 Apr;10(4):1137-42. doi: 10.1016/s0968-0896(01)00388-1. Bioorg Med Chem. 2002. PMID: 11836125

3

Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects.

Suh YG, Lee YS, Min KH, Park OH, Seung HS, Kim HD, Park HG, Choi J, Lee J, Kang SW, Oh UT, Koo JY, Joo YH, Kim SY, Kim JK, Park YH. Suh YG, et al. Among authors: kim jk, kim sy, kim hd. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4389-93. doi: 10.1016/j.bmcl.2003.09.024. Bioorg Med Chem Lett. 2003. PMID: 14643332

4

N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands.

Park HG, Choi JY, Choi SH, Park MK, Lee J, Suh YG, Cho H, Oh U, Kim HD, Joo YH, Kim SY, Park YH, Jeong YS, Choi JK, Kim JK, Jew SS. Park HG, et al. Among authors: kim jk, kim sy, kim hd. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6. doi: 10.1016/j.bmcl.2004.01.041. Bioorg Med Chem Lett. 2004. PMID: 15026052

5

Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands.

Park HG, Choi JY, Kim MH, Choi SH, Park MK, Lee J, Suh YG, Cho H, Oh U, Kim HD, Joo YH, Shin SS, Kim JK, Jeong YS, Koh HJ, Park YH, Jew SS. Park HG, et al. Among authors: kim jk, kim mh, kim hd. Bioorg Med Chem Lett. 2005 Feb 1;15(3):631-4. doi: 10.1016/j.bmcl.2004.11.033. Bioorg Med Chem Lett. 2005. PMID: 15664827

6

Novel potent antagonists of transient receptor potential channel, vanilloid subfamily member 1: structure-activity relationship of 1,3-diarylalkyl thioureas possessing new vanilloid equivalents.

Suh YG, Lee YS, Min KH, Park OH, Kim JK, Seung HS, Seo SY, Lee BY, Nam YH, Lee KO, Kim HD, Park HG, Lee J, Oh U, Lim JO, Kang SU, Kil MJ, Koo JY, Shin SS, Joo YH, Kim JK, Jeong YS, Kim SY, Park YH. Suh YG, et al. Among authors: kim jk, kim sy, kim hd. J Med Chem. 2005 Sep 8;48(18):5823-36. doi: 10.1021/jm0502790. J Med Chem. 2005. PMID: 16134949

7

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.

Kim E, Park CS, Han T, Bae MH, Chong W, Lee CH, Shin YA, Ahn BN, Kim MK, Shin CY, Son MH, Kim JK, Moon HS, Shim HJ, Kim EJ, Kim SH, Lim JI, Lee CH. Kim E, et al. Among authors: kim jk, kim ej, kim sh, kim mk. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4993-6. doi: 10.1016/j.bmcl.2008.08.020. Epub 2008 Aug 12. Bioorg Med Chem Lett. 2008. PMID: 18771917

8

Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.

Yu Y, Jang M, Miyashiro J, Clark RF, Zhu GD, Gong J, Dai Y, Frey RR, Penning TD, Kim H, Lee HK, Kim JK, Ryu KM, Park SJ, Yoon T, Li T, Kurnick MD, Kapecki NJ, Li L, Gorman JV, Montgomery DA, Manaves V, Bromberg KD, Doktor SZ, Thakur A, Wang J, Smith HA, Buchanan FG, Ferguson DC, Torrent M, Jakob CG, Qiu W, Upadhyay AK, Martin RL, Lai A, Michaelides MR. Yu Y, et al. Among authors: kim h, kim jk. J Med Chem. 2024 Oct 10;67(19):17000-17032. doi: 10.1021/acs.jmedchem.4c01450. Epub 2024 Sep 16. J Med Chem. 2024. PMID: 39283694

9

PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.

Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY. Kim MK, et al. Among authors: kim e, kim jk, kim sh. Eur J Pharmacol. 2008 Oct 24;595(1-3):119-25. doi: 10.1016/j.ejphar.2008.07.066. Epub 2008 Aug 12. Eur J Pharmacol. 2008. PMID: 18727927

10

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.

Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY. Kim MK, et al. Among authors: kim jk, kim sh, kim hs, kim jg. Arch Pharm Res. 2009 May;32(5):721-7. doi: 10.1007/s12272-009-1511-8. Epub 2009 May 27. Arch Pharm Res. 2009. PMID: 19471887

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,501 results

Search Page

Filters